How This Company Went From Nothing To $4 Billion!

Kevin Sayer spent 15 years as CEO of Dexcom, growing it from a niche startup into a $4 billion company that created the continuous glucose monitoring industry from scratch. In this episode of No Spotlight Needed, he sits down with Sheetal to tell the whole story: the early bets, the hard lessons, the bold moves, and what it really took to build something that has saved lives around the world. Kevin opens up about his recent cancer diagnosis and recovery, the toughest quarter of his career in 2024, why he delayed the G4 launch and tanked the stock price, the Super Bowl ad decision, the Google partnership, how Dexcom responded to the GLP-1 threat, and why he stepped down on his own terms. This is a masterclass in long-term thinking, accountability, and building a business you believe in. Let's connect: LinkedIn: / sheetal-mehta-prasad Our Website: https://www.nospotlightneeded.com Subscribe to the Channel: / @nospotlightneeded 0:00 - Teaser: stock from 17 to 6, never run a business to sell it, creating an industry 0:53 - Introduction: Kevin Sayer and the Dexcom story 2:30 - Kevin's cancer diagnosis, surgery, chemo, and being cancer free 3:34 - Reversing back to 2024: the hardest stretch of Kevin's tenure 4:33 - How Dexcom responded: accountability, no excuses, staying the course 6:05 - Speed, level-headed decisions, and not forgetting how remarkable the company is 7:10 - Meeting with the commercial team every single day 7:38 - The whiteboard lesson: identifying who your customer really is 9:03 - Calling distributors directly and getting hands on 9:37 - Kevin's leadership style: always a little more hands on than hands off 10:02 - Growing up in Idaho: grandfather's Jeep dealership, washing cars at 12 11:04 - Never judge anyone by what they're wearing: the lesson from his father 12:28 - Driving the car lots at night: how his father thought about customer retention 13:05 - All jobs are good: where accountability and work ethic came from 13:40 - First job in diabetes: CFO of Mini Med under Alfred Mann 14:07 - He lied about the $10M raise. Kevin showed up anyway and closed the deal. 15:16 - What Alfred Mann taught him: tenacity until the very last day 16:09 - We all get where we get because someone gave us a chance we didn't deserve 16:27 - The hospital bed visit: Al showing Kevin an implantable pump while dying 17:37 - Mini Med acquired by Medtronic for $3.5 billion in 2001 18:16 - Why Mini Med never really fit inside Medtronic 19:58 - Never run a business to sell it: the lesson from Mini Med 21:33 - Specialty Labs, Biosensors, and the years between Mini Med and Dexcom 22:18 - His wife told him he was the most unhappy she had ever seen him 23:10 - Nobody offered him an operating role. His reputation was finance. 24:29 - Joining the Dexcom board in 2007 while at Biosensors 25:14 - The decision to join Terry Gregg and move the family to San Diego 26:11 - Terry's recruiting lesson: how do you want to do this? 27:22 - What made Terry Gregg a remarkable leader 28:39 - If you listened when Terry was angry, there was always truth in it 29:25 - How Terry spent his retirement making Kevin successful 30:35 - The G4 decision: Kevin's first call as president drove the stock from 17 to 6 31:36 - "This product isn't good enough and they know how to fix it but they're afraid" 32:19 - Daily meetings with the engineers and the October 15th deadline 33:04 - Why G4 was the pivotal moment in the company's history 33:58 - What the engineers were afraid of: testing and testing and never pulling the trigger 35:04 - Scaling from $76M to $600M: what was actually critical 35:38 - The three layers: technology first, then commercial, then manufacturing 38:27 - Going to the phone and the data sharing breakthrough 40:35 - The email from the law student in Topeka whose life was saved 41:30 - Parents going on dates again. Grandparents being monitored from across the state. 42:05 - What they underestimated: the reaction when it didn't work 44:29 - The Super Bowl ad debate: $5.5 million for 30 seconds 44:55 - His father's last call: do you have enough inventory and what are you going to do about ads? 46:29 - Why consumer marketers changed everything for Dexcom 46:52 - The text from UnitedHealthcare: this is very cool 47:29 - The awareness probably helped competitors too. Worth it anyway. 48:00 - The second Super Bowl ad for G7: $7 million in 2023 48:42 - Stella and the natural extension to direct-to-consumer 49:08 - The Google partnership: why Kevin did not want Google to anoint Abbott or Medtronic 50:08 - What the Google partnership actually gave them: credibility and the push to G7 51:00 - Partnerships are not marriages: everybody is still looking out for their own interest 51:54 - How GLP-1s forced Dexcom to embrace disruption rather than run from it 54:10 - You just embrace it: how to lead when investors say you're obsolete 55:32 - Stepping down: the decision to retire before anyone pushed him out